文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

特发性肺纤维化中定量CT纤维化程度变化的有意义阈值

Meaningful thresholds for change in quantitative computed tomography-derived fibrosis extent in idiopathic pulmonary fibrosis.
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01
一句话结论多中心回顾性研究显示,IPF患者1年定量CT纤维化评分变化≥4.05%与无移植生存期独立相关,支持每年CT随访并预设QCT阈值进行风险分层。

该多中心回顾性研究纳入基线及1年随访CT的IPF患者,用锚定法基于FVC和DLco变化估算纤维化评分变化(ΔFS)的最小临床重要差异(MCID),并用最大选择log-rank统计量确定预后阈值。发现队列524例(平均66.8岁,79%男性),外部验证队列224例(平均69.6岁,83%男性)。基于FVC和DLco的MCID分别为2.72%和4.52%,预后阈值为4.05%。验证队列中ΔFS与无移植生存期相关(aHR=1.11;95%CI 1.04-1.18),ΔFS≥4.05%与总生存(aHR=2.78;95%CI 1.36-5.68)和3年无移植生存(aHR=2.88;95%CI 1.11-7.48)关联最一致。

要点

  • IPF患者1年定量CT纤维化评分变化(ΔFS)与无移植生存期独立相关,验证队列aHR=1.11(95%CI 1.04-1.18)。
  • 基于FVC的MCID为2.72%,基于DLco的MCID为4.52%,预后阈值为4.05%。
  • ΔFS≥4.05%与总无移植生存(aHR=2.78;95%CI 1.36-5.68)和3年无移植生存(aHR=2.88;95%CI 1.11-7.48)关联最一致。
  • 发现队列中ΔFS超过MCID或预后阈值时风险更高(均P<.001)。
  • 作者认为上述结果支持IPF患者每年CT随访并预设QCT阈值进行监测和风险分层。

适用人群与场景

  • 特发性肺纤维化(IPF)患者,具有基线和1年随访CT;发现队列524例(平均年龄66.8岁,79%男性),外部验证队列224例(平均年龄69.6岁,83%男性)。

诊断标准与关键阈值

  • 纤维化评分变化(ΔFS)的MCID:基于FVC为2.72%,基于DLco为4.52%;预后阈值为4.05%。

研究设计与关键结果

  • 多中心回顾性研究,发现队列524例、外部验证队列224例IPF患者,评估1年QCT纤维化评分变化(ΔFS)的MCID和预后阈值。
  • 基于FVC和DLco的MCID分别为2.72%和4.52%,预后阈值为4.05%。
  • 发现队列中1年ΔFS与无移植生存期独立相关,ΔFS超过MCID或预后阈值时风险更高(均P<.001)。
  • 验证队列中ΔFS与无移植生存期相关(aHR=1.11;95%CI 1.04-1.18),ΔFS≥4.05%与总无移植生存(aHR=2.78;95%CI 1.36-5.68)和3年无移植生存(aHR=2.88;95%CI 1.11-7.48)关联最一致。

证据类型、等级与局限

  • 证据类型:多中心回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,1年纤维化评分变化及其阈值与无移植生存期显著相关,支持对IPF患者每年进行CT随访并预设QCT阈值用于监测和风险分层。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

RATIONALE: Validated thresholds for clinically meaningful change in quantitative computed tomography (QCT) for fibrosis extent across algorithms remain unclear in idiopathic pulmonary fibrosis (IPF).

OBJECTIVES: To evaluate minimal clinically important difference (MCID) for 1-year change in QCT metrics in IPF using different algorithms than previously reported and to identify prognostically meaningful thresholds for effective risk stratification.

METHODS: This multicenter retrospective study included IPF patients with baseline and 1-year follow-up CT. Minimal clinically important differences for change in fibrosis score (ΔFS) derived from fully automated CT quantification were estimated using an anchor-based approach with 1-year changes in FVC and diffusing capacity for carbon monoxide (DLco), and a prognostic threshold was estimated using maximally selected log-rank statistics. Prognostic significance of ΔFS was evaluated in discovery and validation cohorts.

RESULTS: The discovery cohort included 524 patients (mean age = 66.8 years; 79% men), and the external validation cohort included 224 patients (mean age = 69.6 years; 83% men). Anchor-based MCIDs were 2.72% for FVC and 4.52% for DLco, with a prognostic threshold of 4.05%. In the discovery cohort, 1-year ΔFS were independently associated with transplant-free survival (TFS), with greater risk when ΔFS exceeded MCID or prognostic thresholds (all, P < .001). In the validation cohort, ΔFS remained associated with TFS (adjusted hazard ratio [aHR] = 1.11; 95% CI, 1.04-1.18), and all prespecified ΔFS thresholds were prognostic for overall TFS, with the prognostic threshold of ΔFS ≥ 4.05% showing the most consistent associations with overall (aHR = 2.78; 95% CI, 1.36-5.68) and 3-year TFS (aHR = 2.88; 95% CI, 1.11-7.48).

CONCLUSION: One-year change in FS and its thresholds were significantly associated with TFS, supporting annual CT follow-up with predefined QCT thresholds for monitoring and risk stratification in IPF.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Kim DY, Kim MJ, Oh YJ, et al. Meaningful thresholds for change in quantitative computed tomography-derived fibrosis extent in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2026. PMID: 42178804. doi:10.1093/ajrccm/aamag245

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。